Cargando…

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance

The development of patient-derived tumor organoids (TOs) from an epithelial ovarian cancer tumor obtained at the time of primary or interval debulking surgery has the potential to play an important role in precision medicine. Here, we utilized TOs to test front-line chemotherapy sensitivity and to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gorski, Justin W., Zhang, Zhuwei, McCorkle, J. Robert, DeJohn, Jodi M., Wang, Chi, Miller, Rachel W., Gallion, Holly H., Dietrich, Charles S., Ueland, Frederick R., Kolesar, Jill M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394135/ https://www.ncbi.nlm.nih.gov/pubmed/34440225 http://dx.doi.org/10.3390/biomedicines9081021

Ejemplares similares

CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
por: Gorski, Justin W., et al.
Publicado: (2020)

Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
por: Schweer, David, et al.
Publicado: (2021)

Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment
por: McDowell, Anthony, et al.
Publicado: (2021)

Human macrophage-engineered vesicles for utilization in ovarian cancer treatment
por: Schweer, David, et al.
Publicado: (2023)

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
por: McCorkle, J. Robert, et al.
Publicado: (2021)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer
por: Hutchcraft, Megan L., et al.
Publicado: (2021)

Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted Therapy
por: Harbin, Laura M., et al.
Publicado: (2022)

Ultrasonographic Visualization of the Ovaries to Detect Ovarian Cancer According to Age, Menopausal Status and Body Type
por: Pavlik, Edward J., et al.
Publicado: (2022)

Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers—Stage Challenges Categorical Assignments of Indolence & Aggressiveness
por: Pavlik, Edward J., et al.
Publicado: (2020)

Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy
por: Schweer, David, et al.
Publicado: (2022)

SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer
por: Harbin, Laura M., et al.
Publicado: (2023)

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
por: Myint, Zin W., et al.
Publicado: (2022)

Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery
por: Smith, Christopher G., et al.
Publicado: (2019)

KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer
por: Hill, Kristen S., et al.
Publicado: (2021)

Implementation of Nurse Navigation Improves Rate of Molecular Tumor Testing for Ovarian Cancer in a Gynecologic Oncology Practice
por: Rives, Taylor A., et al.
Publicado: (2023)

Significance of Pelvic Fluid Observed during Ovarian Cancer Screening with Transvaginal Sonogram
por: Gorski, Justin W., et al.
Publicado: (2022)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Rhetorical delivery as technological discourse : a cross-historical study /
por: McCorkle, Ben, 1974-
Publicado: (2012)

Cell-Derived Vesicles for in Vitro and in Vivo Targeted Therapeutic Delivery
por: Snell, Aaron A., et al.
Publicado: (2019)

A rare case of dual expression of CD5 and CD10 in primary central nervous system diffuse large B‐cell lymphoma with prominent starry sky appearance
por: McCorkle, Colin, et al.
Publicado: (2020)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems
por: Patra, Bishnubrata, et al.
Publicado: (2020)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer: COM33 sensitizes ovarian cancer to carboplatin
por: Zhou, Zhiyang, et al.
Publicado: (2022)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

Cell Context Dependent p53 Genome-Wide Binding Patterns and Enrichment at Repeats
por: Botcheva, Krassimira, et al.
Publicado: (2014)

Psychological Distress during Ovarian Cancer Treatment: Improving Quality by Examining Patient Problems and Advanced Practice Nursing Interventions
por: O'Sullivan, Cynthia Kline, et al.
Publicado: (2011)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer
por: Konstantinopoulos, Panagiotis A, et al.
Publicado: (2008)

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer
por: Pénzváltó, Zsófia, et al.
Publicado: (2014)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
por: Gao, Bo, et al.
Publicado: (2018)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin
por: Zhang, Jinli, et al.
Publicado: (2017)

Exploration of the sequential gene changes in epithelial ovarian cancer induced by carboplatin via microarray analysis
por: Wei, Shuqing, et al.
Publicado: (2017)

Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer
por: Mikkelsen, Mette Schou, et al.
Publicado: (2020)

Macrophage-Engineered Vesicles for Therapeutic Delivery and Bidirectional Reprogramming of Immune Cell Polarization
por: Neupane, Khaga R., et al.
Publicado: (2021)

Multidisciplinary Specialty Teams: A Self-Management Program for Patients With Advanced Cancer
por: Tocchi, Christine, et al.
Publicado: (2015)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_7cshjhrsqh6fgvpgtaattlsu1e